A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)

Paused · Phase 2

Conditions studied: Diffuse, Intrinsic Pontine Glioma

In brief

Current therapies for diffuse, intrinsic pontine glioma (DIPG) provide very limited benefit to the patient. The rationale for the use of Antineoplaston therapy in this protocol study derives from experience with subjects from prior Phase 2 studies and Compassionate Exemption patients treated with Antineoplaston therapy at the Burzynski Clinic. This study is designed to analyze the efficacy and safety of Antineoplaston therapy in five separate DIPG patient cohorts, which are defined by age and prior therapy. This is a two stage study with 20 patients in each cohort being enrolled in the first stage and an additional 20 patients being enrolled in the second stage, if pre-determined efficacy endpoints in the first stage are realized.

Key facts

Study ID
NCT02742883
Run by
Burzynski Research Institute
People needed
1
Starts
2016-04-13
Expected to finish
2028-03-01
Last updated by the study team
2025-09-16

Who can join

Age: 0 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.